8-KLeadership ChangesExhibits & Filings

GILEAD SCIENCES, INC. 8-K Report, Executive Changes (Jul 26, 2018)

Filed July 26, 2018For Securities:GILD

Summary

This 8-K filing from Gilead Sciences, Inc. (GILD) announces significant leadership changes. Effective December 31, 2018, or earlier upon the appointment of a successor, John F. Milligan, Ph.D., will step down as President and Chief Executive Officer and resign from the Board of Directors. Dr. Milligan will remain an employee to assist with the transition through February 28, 2019. The filing also notes that John Martin, Ph.D., Chairman of the Board, intends to step down concurrently with the naming of the new CEO. These executive transitions signal a pivotal moment for Gilead, suggesting a period of strategic re-evaluation and potential new leadership direction. Investors should closely monitor the selection process for a new CEO, as this individual will be instrumental in shaping the company's future strategy, particularly in its key therapeutic areas and ongoing research and development efforts.

Key Highlights

  • 1John F. Milligan, Ph.D. to resign as President and CEO effective December 31, 2018 (or earlier upon successor appointment).
  • 2John F. Milligan to transition out of his role, assisting with handover through February 28, 2019.
  • 3John Martin, Ph.D., Chairman of the Board, intends to step down when the new CEO is appointed.
  • 4The filing is primarily focused on executive officer and director departures.
  • 5Compensation arrangements for Dr. Milligan's transition are to be filed once finalized.

Frequently Asked Questions

The primary reason for this 8-K filing is to announce the planned departure of Gilead's President and Chief Executive Officer, John F. Milligan, Ph.D., and the intention of the Chairman of the Board, John Martin, Ph.D., to step down.

John F. Milligan, Ph.D., is expected to step down as President and CEO on December 31, 2018, or earlier if a successor is appointed and begins their role before that date.

Yes, Dr. Milligan has agreed to remain an employee to assist with transitional matters through February 28, 2019, following his resignation as President and CEO.

The filing states that compensation arrangements in connection with Dr. Milligan's transition and separation will be filed once they have been finalized. This information was not yet available at the time of this filing.